Searchlight Pharma Inc., 2024
Acting for the shareholders of Searchlight Pharma Inc., a top-growth Canadian specialty and innovative branded pharmaceutical company, in connection with the sale of their 100% interest to Apotex Inc., Canada’s largest pharmaceutical company.
Bruker Corporation, 2024
Acted for Bruker Corporation in its acquisition of Tornado Spectral Systems Inc., a company that provides chemical analysis and measurement systems for Raman spectroscopy primarily used in pharmaceutical, petrochemical, and biotechnology applications.
BELLUS Health Inc., 2023
Acted for BELLUS Health Inc. in its US$2-billion sale to GSK plc, a British-based pharmaceutical company.
Cordis-X, 2023
Acted for Cordis-X, the lead investor in the C$34-million Series A funding round by Puzzle Medical Devices Inc., a medical device company specializing in the development of a minimally invasive long-term hemodynamic transcatheter pump.
Apotex International Inc., 2023
Acted as lead tax counsel and Canadian transaction counsel to Apotex International Inc., a global pharmaceutical company that produces high-quality affordable medicine, in the sale of a 50% interest in Arrotex Pharmaceuticals (Australia) to DBG Health.
Pomerleau Inc., 2023
Acted for Pomerleau Inc. in connection with the development phase of the progressive design-build-finance of the Weeneebayko Area Health Authority (WAHA) Project.
Smile CDR Inc., 2023
Acted for Smile CDR Inc. (doing business as Smile Digital Health), a leading FHIR® health data fabric (HDF) and exchange solutions provider, in its approximately $30-million Series B funding round led by existing investors.
Dafabasa, 2023
Acted for Dafabasa, lead investor in the C$4-million extension of the Series A funding round by AmacaThera Inc., a clinical-stage biotechnology company focused on non-opioid post-operative pain relief.
Apotex Pharmaceutical Holdings Inc., 2023
Acted as lead transaction and tax counsel to Apotex Pharmaceutical Holdings Inc., a global pharmaceutical company that produces high-quality affordable medicine, in its sale to SK Capital Partners.
ShockWave Medical, Inc., 2023
Acted as Canadian counsel to Nasdaq-listed Shockwave Medical, Inc., in its acquisition of Nasdaq- and TSX-listed British Columbia–based Neovasc Inc., for a total transaction value of up to US$147 million consisting of a purchase price per share of cash and a contingent value right.
Alaris Equity Partners, 2023
Acted for Alaris Equity Partners, in its US$546-million investment with Brookfield Special Investments, in Body Contour Centers LLC.
OMERS Administrative Corporation, 2023
Acting for OMERS Administration Corporation in its US$200-million acquisition of 54.5% stake of global royalties on MAVYRET, from Enanta Pharmaceruticals, Inc.
Stifel Nicholaus Canada Inc., 2022
Acted for a syndicate of underwriters led by Stifel Nicolaus Canada Inc. in OpSens Inc.'s $11.5-million bought deal public offering of common shares including the full exercise of the over-allotment option by the underwriters.
OMERS Capital Markets, 2022
Acted for OMERS Capital Markets in its US$500-million acquisition of 30% of Ultragenyx Pharmaceutical Inc.'s royalty interest from Kyowa Kirin Co., Ltd. on the future sales of Crysvitar (burosumab) in the United States and Canada.
Bruker Corporation, 2022
Acted for Bruker, a Nasdaq-listed provider of scientific instruments and analytical and diagnostic solutions, in its acquisition of Neurescence Inc., a Toronto-based innovative provider of optical functional neuroimaging.
KKR, 2022
Acted as Canadian counsel to KKR, a leading global investment firm, in its equity investment in connection with the strategic merger of 123Dentist with Altima Dental and Lapointe Group. The merger creates one of the largest dental support organizations in Canada, with nearly 350 supported dental practices.
IDEXX Laboratories, Inc., 2022
Acted for IDEXX Laboratories, Inc., a leader in the design, development and marketing of diagnostic test instruments to monitor animal health and analyze dairy products and water, in its acquisition of the assets of Pathogen Detection Systems, Inc.
BELLUS Health Inc., 2022
Acted for BELLUS Health Inc. in its US$176-million public offering (including the full exercise of the over-allotment option by the underwriters) in Canada and in the United States.
Apotex Inc., 2022
Acting for Apotex Inc. and related entities in defending a class action commenced in the Federal Court of Canada alleging anti-competitive conduct regarding the sale of generic drugs in Canada.
McKesson Corporation, 2021
Acting for McKesson Corporation in the sale of ClaimSecure Inc., an industry-leading healthcare management firm, to The Canada Life Assurance Company, a subsidiary of Great-West Lifeco Inc.
Alexion Pharmaceuticals Inc., 2021
Acted as Canadian competition counsel for Alexion Pharmaceuticals Inc., a global biopharmaceutical company focused on rare disorders therapies, in its US$39-billion acquisition by AstraZeneca plc, a UK-based biopharmaceutical company focused on prescription medicines.
BELLUS Health Inc., 2021
Acted for BELLUS Health Inc. in its US$200-million public offering in Canada and the United States.
Paladin Labs Inc., 2021
Acted for Paladin Labs Inc. in connection with the partnership of Endo International plc and ADVANZ PHARMA Corp. Limited, which resulted in Paladin Labs commercializing and distributing Xydalba (dalbavancin hydrochloride) on an exclusive basis in Canada.
Knight Therapeutics Inc., 2021
Acted for Knight Therapeutics Inc. in its exclusive supply and distribution agreement with Incyte Biosciences International Sàrl for the exclusive rights to distribute tafasitamab (sold as Monjuvir in the United States and Minjuvir in Europe) and pemigatinib (Pemazyrer) in Latin America.
Knight Therapeutics Inc., 2021
Acted for Knight Therapeutics Inc. (TSX: GUD), a pan-America specialty pharmaceutical company, in its acquisition from Novartis of the exclusive rights to manufacture, market and sell Exelon (rivastigmine patch, capsules and solution) in Canada and Latin America, for the purchase price of US$168 million and an additional milestone payment of up to US$12 million on the achievement of certain conditions.
Canadian Imperial Bank of Commerce, 2021
Acted for Canadian Imperial Bank of Commerce in establishing a $1.3-billion senior credit facility and a $250-million bridge facility for the $950-million initial public offering by dentalcorp Holdings Ltd., Canada's largest network of dental practices.
Triage Technologies Inc., 2021
Acted for Triage Technologies Inc., a leader in dermatological mobile health, in connection with the strategic equity investment and licensing agreement with Advanced Human Imaging Limited.
PCL Investments Canada Inc., 2021
Acted for a syndicate of lenders comprised of ATB Financial, Fédération des caisses Desjardins du Québec, The Bank of Nova Scotia, Toronto-Dominion Bank and Business Development Bank of Canada in the establishment of a senior secured credit facility to partially finance the design and construction of the $2.174-billion New St. Paul's Hospital Project (Phase 1a) in Vancouver, British Columbia.
Beattie Pet Hospitals, 2021
Acted for Beattie Pet Hospitals in the sale of substantially all of their assets to National Veterinary Associates, which consists of five veterinary clinics located in Ancaster, Burlington, Stoney Creek, Brantford and Hamilton.
Rexall Pharmacy Group, 2021
Acted for Rexall Pharmacy Group in the sale of its Ontario and northern Alberta long-term care pharmacy business to CareRx Corporation, Canada's leading provider of pharmacy services to seniors and other congregate care communities.
A holding company, 2021
Acting for a holding company in defending contract and related intellectual property claims brought by a former shareholder of a portfolio company.
Caisse de dépôt et placement du Québec, 2021
Acted for Caisse de dépôt et placement du Québec in Dialogue Health Technologies Inc.'s initial public offering.
AiPharma Global Holdings LLC, 2021
Acting for AiPharma Global Holdings LLC, a private pharmaceutical research, development and commercialization company, in its 19.4% PIPE investment in Appili Therapeutics Inc., a biopharmaceutical company sponsoring late-stage clinical trials evaluating the antiviral Avigan/Reeqonus for the treatment and prevention of COVID-19.
New Look Vision Group Inc., 2021
Acted for New Look Vision Group Inc. in its $800-million sale to NL1 AcquireCo Inc., an entity created by funds managed by FFL Partners, LLC, a San Francisco-based private equity firm, Caisse de dépôt et placement du Québec and the Dr. H. Doug Barnes Family.
Searchlight Pharma Inc., 2021
Acted for Searchlight Pharma Inc., a Montréal-based specialty healthcare company, in its acquisition of ERFA Canada 2012 Inc., a distributor of niche pharmaceutical products across Canada that addresses underserved medical indications.
Smile CDR Inc., 2021
Acted for Smile CDR Inc. in a Series A financing round, raising US$20 million to further develop Smile CDR's health data storage and integration platform.
Stifel Nicolaus Canada Inc., 2021
Acted for a syndicate of underwriters led by Stifel Nicolaus Canada Inc. in OpSens Inc.'s $28.75-million bought deal public offering of common shares including the full exercise of the over-allotment option by the underwriters.
Apotex Inc., 2020
Acted as lead transaction and tax counsel to Apotex Inc. and ApoPharma USA Inc. on the sale of the ApoPharma business, including the global rights to Deferiprone, an iron chelator used to treat iron overload conditions resulting from blood transfusions, to Chiesi Farmaceutici S.p.A.
Plenary Group, 2020
Acted for Plenary Group in the acquisition of a portfolio of Ontario-based hospitals and long-term care facilities from OMERS Infrastructure. The portfolio included three hospitals (Niagara Health System-St. Catharine's Hospital, the Royal Ottawa Hospital, the William Osler Health Centre) and 12 long-term care facilities that were constructed by OMERS, then Borealis Infrastructure, through separate greenfield developments between 2000 and 2009.
Knight Therapeutics Inc., 2020
Acted for Knight Therapeutics Inc. in the negotiation of a supply and marketing agreement with Debiopharm Research & Manufacturing SA for the relaunch and commercialization of Trelstar in Canada.
Plenary Americas, 2020
Acted for Avalon Healthcare Partnership, led by Plenary Americas, as the successful consortium for the design, build, finance and maintenance of a new adult mental health and addictions hospital in St. John's, Newfoundland. The project included a 240,000 square foot, six-storey, 102-bed hospital; a parking garage with space for 1,000 vehicles; and a new 60-bed hostel to replace the Agnes Cowan Hostel.
Knight Therapeutics Inc., 2020
Acted for Knight Therapeutics Inc. in its transformative acquisition of all of the issued and outstanding shares of Biotoscana Investments S.A., a Luxembourg company listed on the Brazilian stock exchange, for an aggregate purchase price of $369 million.
Paladin Labs Inc., 2020
Acted for Paladin Labs, an Endo company, in its licensing, commercialization and distribution agreement with Isofol Medical AB of arfolitixorin in Canada, a first-line treatment for metastatic colorectal cancer patients.
TD Securities Inc. and Credit Suisse Securities (Canada), Inc., 2020
Acted for the underwriting syndicate led by TD Securities Inc. and Credit Suisse Securities (Canada), Inc. in MindBeacon Holdings Inc.'s $65-million initial public offering of common shares.
BELLUS Health Inc., 2020
Acted for BELLUS Health Inc. in its US$40-million public offering in the United States.
Equinoxe Virtual Clinic Corp., 2020
Acted for Equinoxe Virtual Clinic Corp., a leading Canadian virtual care provider, in the sale of all of its issued and outstanding shares to Right-Health Inc., a subsidiary of TELUS Corporation and the owner and operator of the Akira virtual care platform.
Bellus Health Inc., 2020
Acted for Bellus Health Inc. in connection with its US$50-million at-the-market offering.
Bank of Montreal, 2020
Acted for Bank of Montreal in its investment in The Fertility Partners, a new venture creating a network of respected fertility clinics across North America.
Seikagaku Corporation, 2020
Acted for Seikagaku Corporation, a Tokyo-based public company in its acquisition of all the outstanding shares of Dalton Chemicals Laboratories, Inc., a leading North American pharmaceutical organization providing integrated drug discovery, development, and manufacturing services.
Searchlight Pharma Inc., 2020
Acted for Searchlight Pharma Inc. in its licensing and distribution agreement with Sprout Pharmaceuticals, Inc. for Addyir in connection with the treatment of Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women.
McKesson Corporation and McKesson Canada Corporation, 2020
Acting for McKesson Corporation and McKesson Canada Corporation to defend a high-profile proposed class action brought by the Province of British Columbia on behalf of all Canadian provincial governments, as well as the Federal government, against manufacturers and distributors of opioids seeking to recover health care costs related to the opioid crisis. Also acting for McKesson in additional opioid-related proposed class actions.
Bellus Health Inc., 2020
Acted for Bellus Health Inc. in its acquisition of the BLU-5937 and related P2X3 antagonists intellectual property assets from adMare BioInnovations' NEOMED Institute.
Fédération des médecins spécialistes du Québec, 2020
Acted for the Fédération des médecins spécialistes du Québec (FMSQ) in defence of a class action relating to fees charged to patients. The group representatives allege that the FMSQ prompted its members to charge certain fees to insured patients in violation of the Health Insurance Act.
Business Development Bank of Canada, 2019
Acted for Business Development Bank of Canada in its investment, as an anchor investor, in Amplitude Ventures, a venture capital fund focused principally on the health and the life sciences sectors.
Knight Therapeutics Inc., 2019
Acted for Knight Therapeutics Inc. in its US$5-million secured bridge loan to Triumvira Immunologics Inc. (Triumvira) to accelerate product development and the negotiation of an exclusive licence to commercialize Triumvira's future approved products for Canada, Israel, Mexico and Colombia.
Association québécoise des pharmaciens propriétaires, 2019
Acting for the Association québécoise des pharmaciens propriétaires in a motion for leave to intervene produced in favour of an application for leave to appeal to the Supreme Court of Canada.
Knight Therapeutics Inc., 2019
Acted for Knight Therapeutics Inc. (licensor) in establishing with Onconova Therapeutics, Inc. a distribution, licensing and supply agreement for the exclusive rights to commercialize rigosertib in Canada.
Knight Therapeutics, 2019
Acted for Knight Therapeutics Inc. in successfully defending against the activist campaign, proxy contest and contested meeting led by Medison Biotech Ltd. with respect to Knight's 2019 annual meeting.
Apotex International Inc., 2019
Acted as tax counsel to Apotex International Inc. in the merger of its Australian and New Zealand generic pharmaceutical and over-the-counter operations with Arrow Pharmaceuticals, the Australian operating business of Strides Ltd., creating Australia's largest generic pharmaceutical and private label OTC business, Arrotex Australia Group.
BELLUS Health Inc., 2019
Acted as counsel to BELLUS Health Inc. in its US$70-million initial public offering in the United States.
Ipsen S.A., 2019
Acted for French biopharmaceutical company Ipsen in the acquisition of Québec-based Clementia Pharmaceuticals for a purchase price of US$25.00 per share in cash upfront, plus a contingent value right (CVR) of US$6.00 per share, for a total transaction value of up to US$1.31 billion.
Celgene Corporation, 2019
Acted for Celgene Corporation, an integrated global biopharmaceutical company, on competition matters related to its US$74-billion sale to Bristol-Myers Squibb Company.
CBHP Limited Partnership, 2019
Acted for CBHP Limited Partnership in its approximately $750-million contract to design, build, finance and maintain the Corner Brook Acute Care Hospital Project in Corner Brook, Newfoundland. The new facility will be attached to the Corner Brook Long Term Care Hospital and will be seven storeys, 600,000 square feet and have 164 beds. Over the course of construction, which is expected to be completed in 2023, the Government of Newfoundland and Labrador said it expects an estimated 4,000 person years of employment and $460 million in GDP to be created.
Triage Technologies Inc., 2019
Advising Triage Technologies Inc., a Toronto-based and AI-powered digital health company, with its business structure, commercial agreements and equity raise.
Pfizer Inc., 2019
Acted for Pfizer Inc. on competition matters in the combination of its consumer healthcare business with GlaxoSmithKline, one of the world's leading research-based pharmaceutical and healthcare companies, to create a new Joint Venture with combined sales of approximately US$12.7 billion.
Healthcare Professionals, 2019
Acting for healthcare professionals in an investigation by a Québec governmental body into the practices of the medical products manufacturing industry. The investigation could give rise to administrative, civil, disciplinary and criminal prosecutions.
Association québécoise des pharmaciens propriétaires, 2019
Acting for the Association québécoise des pharmaciens propriétaires in its constitutional challenge of section 22.6 of the Health Insurance Act.
Altus Formulation Inc., 2019
Acted for Altus Formulation Inc. in its joint venture agreement with Tetra Bio-Pharma Inc. under which the two companies will work together to develop a series of cannabinoid-receptor targeted therapeutics addressing multiple areas of high unmet need.
Knight Therapeutics Inc., 2019
Acted for Knight Therapeutics Inc. with its license agreement with Puma Biotechnology, Inc. for the exclusive right to commercialize NERLYNX in Canada.
McKesson Canada Corporation, 2019
Acting for McKesson Canada Corporation in Purdue Pharma's voluntary proceedings under Companies' Creditors Arrangement Act in Canada and Chapter 11 of the U.S. Bankruptcy Code.
Endo International plc, 2019
Acted for Endo Ventures Limited, a subsidiary of Endo International plc, with its agreement with Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, to register, commercialize, and distribute Pracinostat on an exclusive basis in Canada.
Knight Therapeutics Inc., 2018
Acted for Knight Therapeutics Inc. (Knight) in a Distribution, License and Supply Agreement with Jaguar Health, Inc.
Ergoresearch Ltd., 2018
Acted for the management shareholders of Ergoresearch Ltd., a company listed on the TSX Venture Exchange, in a going-private transaction in partnership with Walter Capital Partners Inc.
Knight Therapeutics Inc., 2018
Acted for Knight Therapeutics Inc. in Aralez Pharmaceuticals Inc.'s voluntary proceedings under Companies' Creditors Arrangement Act and Chapter 11 of the U.S. Bankruptcy Code.
Searchlight Pharma, 2018
Acted for Searchlight Pharma in the signing of an exclusive licensing agreement to commercialize Estelle® in Canada.
Altus Formulation Inc., 2018
Acted for Altus Formulation Inc., in various matters, including pertaining to the exclusive licensing and commercialization of the Flexitab Product Portfolio by Searchlight Pharma Inc.
Association québécoise des pharmaciens propriétaires, 2018
Acting for the Association québécoise des pharmaciens propriétaires in a motion for declaratory judgment against the Attorney General of Québec and the Régie de l'assurance maladie du Québec concerning the interpretation of a recent statute adopted by the Québec legislature regarding certain obligations imposed upon all pharmacists in Québec.
BASF SE, 2018
Acted for BASF SE on competition matters in the merger of its paper and water chemicals business with Solenis LLC to create a global specialty chemical company.
CHAMP Private Equity Pty. Limited, 2018
Acted as Canadian counsel for CHAMP Private Equity Pty. Limited in its acquisition of Cell Care and its subsidiary Insception Biosciences Inc., a consumer health company with operations across Australia and Canada that collects, processes and stores umbilical cord stem cells.
Apotex International Inc., 2018
Acted as tax counsel to Apotex International Inc. in the sale of its commercial operations and certain supporting infrastructure for its generics business in five European countries to Aurobindo Pharma Limited.
BELLUS Health Inc., 2018
Acted for BELLUS Health Inc. in its $35-million overnight marketed offering of common shares to support the development of its lead drug candidate BLU-5937 for chronic cough.
WellSpring Pharma Services Inc., 2018
Acted as Canadian counsel to WellSpring and its shareholders in the US$18-million sale of WellSpring Pharma Services Inc. to ANI Pharmaceuticals Inc.
Caisse de dépôt et placement du Québec, 2018
Acted for Caisse de dépôt et placement du Québec (CDPQ) in (i) the sale of Knowlton Development Corporation's shares to a group of investors, including HarbourVest Partners, LLC, led by Cornell Capital LLC; and (ii) the rollover of CDPQ's shares and additional investment therein.
Searchlight Pharma Inc., 2018
Acted for Searchlight Pharma Inc. in its acquisition from Norgine B.V.'s subsidiary, Merus Labs International Inc., of its Canadian assets relating to Enablex and Vancocin.
McKesson Canada Corporation and McKesson Corporation, 2018
Acted for McKesson Canada Corporation and McKesson Corporation in a $200-million contractual indemnity claim arising out of the purchase of the Rexall Pharmacy Business and tort claims for alleged fraudulent misrepresentations in contract negotiation.
Paladin Labs, 2018
Acted for Paladin Labs, an Endo company in its licensing and distribution arrangements with Britannia Pharmaceuticals Limited, a UK company, concerning Movapor in connection with Parkinson's Disease.
Paladin Labs, 2018
Acted for Paladin Labs, an Endo company in its licensing, commercialization and distribution agreement with Bioprojet SCR for Wakixr in connection with narcolepsy.
Ayana Pharma Ltd., 2017
Advising Ayana Pharma Ltd. on various commercial matters.
Endo International plc, 2017
Represented Endo International plc in a Canadian securities class action alleging that Endo made material misrepresentations and omissions concerning (i) its receipt of "a subpoena from the State of Connecticut about likely antitrust violations concerning" certain products; and (ii) the erosion in its generic pharmaceutical business.
Knight Therapeutics Inc., 2017
Acting for a Canadian specialty pharmaceutical company in negotiating distribution agreements regarding the supply of medical drugs in Colombia, Peru, Ecuador, Paraguay and Israel.
Apotex Holdings Inc., 2017
Acted as tax counsel to Apotex Holdings Inc. in connection with the sale of Accucaps Industries Limited, a developer and manufacturer of over-the-counter pharmaceutical softgels, to Catalent Pharma Solutions.
BELLUS Health Inc., 2017
Acted for BELLUS Health Inc. in connection with the exclusive worldwide licence agreement with The Neomed Institute to develop and commercialize BLU-5937 for the treatment of chronic cough.
BELLUS Health Inc., 2017
Acted for BELLUS Health Inc. in connection with the sale of its wholly owned subsidiary, Thallion Pharmaceuticals Inc., to Taro Pharmaceuticals Inc., including all the rights to the drug candidate ShigamabT.
BELLUS Health Inc., 2017
Acted for BELLUS Health Inc. in its $20-million overnight marketed offering of common shares.
Hearing Panel of the Patented Medicine Prices Review Board, 2017
Acted as counsel to the Hearing Panel of the Patented Medicine Prices Review Board in two proceedings which determined whether Soliris and Procysbi, rare disease medicines, are excessively priced.
Medtronic plc, 2017
Acted as Canadian counsel to Medtronic plc on competition and regulatory matters in the US$6.1-billion acquisition of its patient care, deep vein thrombosis and nutritional insufficiency business by Cardinal Health.
Paladin Labs Inc., 2017
Acted for Paladin Labs, a company of Endo International plc, in connection with its licensing and distribution arrangements with PuraNox Trading BV, a Dutch company, concerning its Puranox medical product.
Paladin Labs Inc., 2017
Acted for Paladin Labs, a company of Endo International plc, in connection with its long-term licensing arrangement with Novintethical Pharma, a Swiss company, for a medical device.
Neovia Probiotics Inc., 2017
Acted for Neovia Probiotics Inc., an indirect subsidiary of a leading French agricultural cooperative group, in its acquisition (by way of a plan of arrangement) of Epicore BioNetworks Inc., a TSXV-listed company specializing in the sale of environmental biological products and specialty feeds.
McKesson Canada, 2017
Acted for McKesson Canada in its acquisition of Well.ca, an online retailer of health, wellness, baby and beauty products.
Pharmacy Quality Solutions, Inc., 2017
Acting for a U.S.-based life sciences technology company, which provides services to insurance companies and pharmacies, in connection with the rollout of its product offering in Canada.
Caisse de dépôt et placement du Québec, 2017
Acted for the Caisse de dépôt et placement du Québec ("CDPQ") in connection with the sale of Atrium Innovations Inc. to Nestlé S.A., for US$2.3 billion. Atrium Innovations Inc. was held by a group of investors that includes Permira Funds, CDPQ and the Fonds de solidarité des travailleurs du Québec (F.T.Q.).
Knight Therapeutics Inc., 2017
Acted for a subsidiary of Knight Therapeutics Inc. on a secured loan of US$10 million to Synergy CHC Corp. to support product acquisitions as well as for general working capital purposes.
Knight Therapeutics Inc., 2017
Acting for Knight Therapeutics Inc. in connection with its exclusive licensing agreement with AstraZeneca for Movantik/Moventig in Canada and Israel.
